ANTUREC related publications

This lists different resources about ANTUREC and it's science. This includes preclinical studies, clinical studies and information on the TRABTRAP study. 

Manufacturer´s Licence - GMP production

The University Hospital of Muenster, Germany (UKM) - together with ANTUREC - holds a GMP manufacturing licence for the IMP tTF-NGR used for multicenter clinical studies

(Manufacturer´s authorisation number DE_NW_05_MIA_2021_0009/24.05.03-034).

Related Publications

This list includes preclinical studies, clinical studies, information on "Good Manufacturing Practice" (GMP) guidelines and information on the tTF-NGR working group of the university hospital Muenster. 

 

Preclinical Studies

  • Kessler, T.; et al. Inhibition of tumor growth by RGD peptide-directed delivery of truncated tissue factor to the tumor vasculature. Clin Cancer Res. 2005, 11, 6317-6324. doi:10.1158/1078-0432.CCR-05-0389.

 

  • Persigehl, T.; et al. Antiangiogenic tumor treatment: early noninvasive monitoring with USPIO-enhanced MR imaging in mice. Radiology. 2007, 244, 449–456. doi: 10.1148/radiol.2442060371.

 

  • Persigehl, T.; et al. Prediction of antiangiogenic treatment efficacy by iron oxide enhanced parametric magnetic resonance imaging. Investig Radiol. 2007, 42, 791–796. doi: 10.1097/RLI.0b013e3180d5cbd9.

 

  • Kessler, T.; et al. Generation of fusion proteins for selective occlusion of tumor vessels. Curr Drug Discov Technol. 2008, 5, 1–8. DOI: 10.2174/157016308783769487.

 

  • Bieker, R.; et al. Infarction of tumor vessels by NGR-peptide directed targeting of tissue factor. Experimental results and first-in-man experience. Blood. 2009, 113, 5019–5027. DOI: 10.1182/blood-2008-04-150318.

 

 

  • Dreischalück, J.; et al. Vascular infarction by subcutaneous application of tissue factor targeted to tumor vessels with NGR-peptides: activity and toxicity profile. Int J Oncol. 2010, 37, 1389–1397. DOI: 10.3892/ijo_00000790.

 

  • Von Maltzahn, G.; et al. Nanoparticles that communicate in vivo to amplify tumour targeting. Nat Mater. 2011, 10, 545–552. DOI: 10.1038/nmat3049.

 

  • Schwöppe, C.; et al. Using native gel electrophoresis or isoelectric focusing as experimental “clock” for the (iso)aspartate formation of tTF-NGR fusion proteins. Biomacromol. Mass Spectrom. 2012, 2, 285–293.

 

  • Schwöppe, C.; et al. Anticancer therapy by tumor vessel infarction with polyethylene glycol conjugated retargeted tissue factor. J Med Chem. 2013, 56, 2337–2347. DOI: 10.1021/jm301669z.

 

  • Persigehl, T.; et al. Non-invasive monitoring of tumor-vessel infarction by retargeted truncated tissue factor tTF-NGR using multi-modal imaging. Angiogenesis. 2014, 17, 235–246. doi: 10.1007/s10456-013-9391-4.

 

  • Brand, C.; et al. Low-energy ultrasound treatment improves regional tumor vessel infarction by retargeted tissue factor. J Ultrasound Med. 2015, 34, 1227–1236. DOI: 10.7863/ultra.34.7.1227.

 

  • Brand, C.; et al. Tumor growth inhibition via occlusion of tumor vasculature induced by N-terminally PEGylated retargeted tissue factor tTF-NGR. Mol Pharm. 2015, 12, 3749–3758. DOI: 10.1021/acs.molpharmaceut.5b00508.

 

  • Brand, C.; et al. NG2 proteoglycan as a pericyte target for anticancer therapy by tumor vessel infarction with retargeted tissue factor. Oncotarget. 2016, 7, 6774-6789. doi: 10.18632/oncotarget.12559.

 

  • Stucke-Ring, J.; et al. Combinatorial effects of doxorubicin and retargeted tissue factor by intratumoral entrapment of doxorubicin and proapoptotic increase of tumor vascular infarction. Oncotarget. 2016, 7, 82458–82472. DOI: 10.18632/oncotarget.12559.

 

  • Schmidt, L.H.; et al. Potential therapeutic impact of CD13 expression in non-small cell lung cancer. PLoS ONE. 2017, 12, e0177146. DOI: 10.1371/journal.pone.0177146.

 

  • Schmidt, L.H.; et al. CD13 as target for tissue factor induced tumor vascular infarction in small cell lung cancer. Lung Cancer. 2017, 113, 121–127. DOI: 10.1016/j.lungcan.2017.09.013.

 

  • Kessler, T.; et al. Aminopeptidase N (CD13): Expression, prognostic impact, and use as therapeutic target for tissue factor induced tumor vascular infarction in soft tissue sarcoma. Transl Oncol. 2018, 11, 1271–1282. DOI: 10.1016/j.tranon.2018.08.004.

 

  • Höink, A.; et al. Gadofosveset-enhanced MRI as simple surrogate parameter for real-time evaluation of the initial tumour vessel infarction by retargeted tissue factor tTF-NGR. Oncol Lett. 2019, 17, 270–280. DOI: 10.3892/ol.2018.9638.

 

  • Brand, C.; et al. Radiation synergizes with antitumor activity of CD13-targeted tissue factor in a HT1080 xenograft model of human soft tissue sarcoma. PLoS ONE. 2020, 15, e0229271. DOI: 10.1371/journal.pone.0229271

 

Clinical Studies

  • Gerwing, M.; et al. The beginning of the end for conventional RECIST—novel therapies require novel imaging approaches. Nat Rev Clin Oncol. 2019, 16, 442–458. DOI: 10.1038/s41571-019-0169-5.
      
  • Schliemann, C.; et al. First-in-class CD13-targeted tissue factor tTF-NGR in patients with recurrent or refractory malignant tumors: results of a phase I dose-escalation study. Cancers. 2020, 12, 1488. DOI: 10.3390/cancers12061488.
      
  • Berdel, W.E.; et al. Animal safety, toxicology, and pharmacokinetic studies according to the ICH S9 guideline for a novel fusion protein tTF-NGR targeting procoagulatory activity into tumor vasculature: are results predictive for humans? Cancers. 2020, 12, 3536. DOI: 10.3390/cancers12123536.
      
  • Gerwing M.; et al. Multiparametric Magnetic Resonance Imaging for Immediate Target Hit Assessment of CD13-Targeted Tissue Factor tTF-NGR in Advanced Malignant Disease. Cancers 2021, 13, 5880, DOI: 10.3390/cancers 1323588.
     
  • Hoffmann, E; et al. Multiparametric MRI for characterization oft he tumour microenvironment. Nat Rev Clin Oncol. 2024, 21, 428-448. DOI: 10.1038/s41571-024-00891-1.
     
  • Heßling, K; et al. Trabectedin versus trabectedin plus CD13-targeted tissue factor tTF-NGR in patients with advanced relapsed or refractory soft tissue sarcoma: translational data and clinical dose-finding cohort from the TRABTRAP study. Scientific Reports. 2026, 16, 7389. DOI: 10.1038/s41598‑026‑40362‑4.

 

Information on Good Manufacturing Practice (GMP) Guidelines

tTF-NGR Working Group of the University Hospital Muenster

Wir benötigen Ihre Zustimmung zum Laden der Übersetzungen

Wir nutzen einen Drittanbieter-Service, um den Inhalt der Website zu übersetzen, der möglicherweise Daten über Ihre Aktivitäten sammelt. Bitte überprüfen Sie die Details in der Datenschutzerklärung und akzeptieren Sie den Dienst, um die Übersetzungen zu sehen.